The research, presented at the European Society for Medical Oncology Congress Oct. 22, suggests that an IV infusion combination of the antibody drug enfortumab vedotin and the immunotherapy pembrolizumab extends overall survival by a median of 31.5 months, versus 16.1 months with standard chemotherapy.
The phase 3 trial included 886 patients who received three-week cycles of the new combination or standard chemotherapy treatment. The new drug combination had a similar safety profile as chemotherapies, with roughly 14% fewer occurrences of skin rashes or hyperglycemia than seen with standard treatment.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
